Lilly CEO Says Losses Stemmed by Cymbalta, Animal Drug Sales

Eli Lilly & Co. Chief Executive Officer John Lechleiter said rising sales of the antidepressant Cymbalta and animal drugs stemmed losses from generic competition, helping the company’s earnings beat estimates.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.